CINQAIR Market Size, Insight, and Forecast to 2032

This report provides comprehensive insights about CINQAIR for Asthma in the seven major markets. A detailed picture of the CINQAIR for Asthma in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the CINQAIR for Asthma.

The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CINQAIR market forecast analysis for Asthma in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Asthma.

Drug Summary

Reslizumab injection is a humanized interleukin-5 antagonist monoclonal antibody for add-on maintenance treatment of adult patients with severe asthma and an eosinophilic phenotype developed by Teva Pharmaceuticals. CINQAIR is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 and older with an eosinophilic phenotype.

Limitation of use:

• CINQAIR is not indicated for the treatment of other eosinophilic conditions
• CINQAIR is not indicated for the relief of acute bronchospasm or status asthmaticus

Dosage and administration

CINQAIR is for IV infusion only and should not be administered as an IV push or bolus. The recommended dosage regimen is 3 mg/kg once every 4 weeks, administered by IV infusion over 20-50 min. The infusion must be immediately discontinued if the patient experiences a severe systemic reaction, including anaphylaxis. 

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the CINQAIR description, mechanism of action, dosage and administration, research and development activities in Asthma.
• Elaborated details on CINQAIR regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CINQAIR research and development activities in Asthma across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around CINQAIR.
• The report contains forecasted sales of CINQAIR for Asthma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Asthma.
• The report also features the SWOT analysis with analyst views for CINQAIR in Asthma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CINQAIR Analytical Perspective

In-depth CINQAIR Market Assessment

This report provides a detailed market assessment of CINQAIR for Asthma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

CINQAIR Clinical Assessment

The report provides the clinical trials information of CINQAIR for Asthma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Asthma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CINQAIR dominance.
• Other emerging products for Asthma are expected to give tough market competition to CINQAIR and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CINQAIR in Asthma.
• This in-depth analysis of the forecasted sales data of CINQAIR from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CINQAIR in Asthma.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of CINQAIR?
• What is the clinical trial status of the study related to CINQAIR in Asthma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CINQAIR development?
• What are the key designations that have been granted to CINQAIR for Asthma?
• What is the forecasted market scenario of CINQAIR for Asthma?
• What are the forecasted sales of CINQAIR in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to CINQAIR for Asthma?
• Which are the late-stage emerging therapies under development for the treatment of Asthma?

This product will be delivered within 2 business days.